A Feasibility Study of Carboplatin Plus Irinotecan Treatment for Elderly Patients with Extensive Disease Small-cell Lung Cancer

A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer

(2011) A. Schmittel et al.   ANNALS OF ONCOLOGY

Treatment of small-cell lung cancer in elderly patients

(2010) Athanasios G. Pallis et al.   CANCER

Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer

(2010) David S. Ettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy

(2010) Robert Jotte et al.   JOURNAL OF CLINICAL ONCOLOGY

Camptothecins Compared with Etoposide in Combination with Platinum Analog in Extensive Stage Small Cell Lung Cancer: Systematic Review with Meta-Analysis

(2010) João Paulo S.N. Lima et al.   Journal of Thoracic Oncology

Trends in Lung Cancer Incidence by Histological Type in Osaka, Japan

(2008) Y. Toyoda et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial

(2008) Andreas Hermes et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402

(2008) Akira Inoue et al.   JOURNAL OF CLINICAL ONCOLOGY